Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial.

Abstract

Elderly patients are at high-risk of bleeding, but are under-represented in clinical trials. The aims were to determine the incidence and the predictive factors of bleeding and to assess the impact of bleeding on further ischemic outcomes in elderly patients after acute coronary syndrome (ACS) treated with percutaneous coronary intervention. From the 877 patients aged ≥75years included in the ANTARCTIC randomized trial, data on Bleeding Academic Research Consortium (BARC) bleeding complications and major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, myocardial infarction, and stroke, were collected over 1year. Clinically relevant bleeding events (BARC types 2, 3, or 5) were observed in 20.6% of patients (n=181) at 1year, of which, one third occurred in the first month. Anemia (adjusted hazard ratio [adj.HR] 3.98, 95% confidence interval [CI] 1.41-11.22; p=0.009), severe chronic renal failure (adj.HR 1.83, 95% CI 1.12-2.98; p=0.015), and femoral access (adj.HR 2.54, 95% CI 1.71-3.77; p<0.001) were independently associated with clinically relevant bleeding events, while age >85years (adj.HR 2.22, 95% CI 1.14-4.30; p=0.018) was independently associated with major bleeding events (BARC types 3 or 5). Patients with a clinically relevant bleeding event had a higher rate of MACE at 1year (adj.HR 2.04, 95% CI 1.24-3.38; p=0.005), with a particularly strong effect on stroke (adj.HR 5.55, 95% CI 2.04-15.06; p<0.001). Clinically relevant bleeding events were observed in one out of five elderly patients undergoing stenting for an ACS and were strongly associated with further stroke occurrence. Rather than the antiplatelet therapy, comorbidities and an age >85years predicted bleeding outcomes in this elderly population. Clinicaltrials.gov identifier: NCT01538446. https://www.clinicaltrials.gov .